Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
Saved in:
| Title: | Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. |
|---|---|
| Authors: | Ho GF; Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. gwoho@um.edu.my., Chai CS; Department of Medicine, Faculty of Medicine and Health Science, University Malaysia Sarawak, Kota Samarahan, Sarawak, Malaysia., Alip A; Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Wahid MIA; Beacon International Specialist Centre, Kuala Lumpur, Malaysia., Abdullah MM; Subang Jaya Medical Centre, Kuala Lumpur, Malaysia., Foo YC; Subang Jaya Medical Centre, Kuala Lumpur, Malaysia., How SH; Hospital Tengku Ampuan Afzan, Kuantan, Malaysia., Zaatar A; Gleneagles Hospital, Penang, Malaysia., Lam KS; Pantai Hospital, Kuala Lumpur, Malaysia., Leong KW; Gleneagles Hospital, Penang, Malaysia., Low JS; Pantai Hospital, Kuala Lumpur, Malaysia., Yusof MM; Pantai Hospital, Kuala Lumpur, Malaysia., Lee EC; Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Toh YY; Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Liam CK; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. |
| Source: | BMC cancer [BMC Cancer] 2019 Sep 09; Vol. 19 (1), pp. 896. Date of Electronic Publication: 2019 Sep 09. |
| Publication Type: | Journal Article; Multicenter Study; Observational Study |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
